Biotech · Public company · Princeton, NJ, US
PMV Pharmaceuticals, Inc.
Ticker PMVP · SEC CIK 0001699382
Track this companyFree. Adds PMV Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline12
- pembrolizumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- rezatapoptPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- [14C]-PC14586Phase 1 · Healthy Male VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- FamotidinePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- metformin hydrochloride 500 mg tabletPhase 1 · TP53 Y220C MutationClinicalTrials.gov · fetched Nov 12, 2026
- midazolam hydrochloride syrupPhase 1 · TP53 Y220C MutationClinicalTrials.gov · fetched Nov 12, 2026
- PC14586Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- RabeprazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- repaglinide 0.5 mg tabletPhase 1 · TP53 Y220C MutationClinicalTrials.gov · fetched Nov 12, 2026
- rezatapoptPhase 1 · TP53 Y220C MutationClinicalTrials.gov · fetched Nov 12, 2026
- rosuvastatin 10 mg tabletPhase 1 · TP53 Y220C MutationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.PHASE1 · RECRUITING · started Feb 4, 2026ClinicalTrials.gov NCT07372625 · fetched Nov 12, 2026
- A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)PHASE1 · RECRUITING · started Jan 30, 2025ClinicalTrials.gov NCT06616636 · fetched Nov 12, 2026
- A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy ParticipantsPHASE1 · COMPLETED · started Mar 28, 2024ClinicalTrials.gov NCT06362642 · fetched Nov 12, 2026
- A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy ParticipantsPHASE1 · COMPLETED · started Sep 19, 2023ClinicalTrials.gov NCT06054464 · fetched Nov 12, 2026
- AME Study of [14C]-PC14586 in Healthy Male ParticipantsPHASE1 · COMPLETED · started Sep 6, 2022ClinicalTrials.gov NCT05523687 · fetched Nov 12, 2026
- Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese VolunteersPHASE1 · COMPLETED · started Dec 20, 2021ClinicalTrials.gov NCT05249348 · fetched Nov 12, 2026
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1_PHASE2 · RECRUITING · started Oct 29, 2020ClinicalTrials.gov NCT04585750 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 31, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 6, 2026 · fetched Nov 12, 2026